MabCure Inc. (MBCI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerMabCure Inc. (MBCI) trades at $0.00002. MabCure, Inc. is a development stage company focused on developing proprietary antibody technology for cancer detection and therapeutics. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for MBCI: MBCI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
MabCure Inc. (MBCI) Healthcare & Pipeline Overview
MabCure, Inc. is pioneering innovative antibody technology aimed at early cancer detection and therapeutic applications, positioning itself at the forefront of the oncology market with a focus on proprietary monoclonal antibodies.
What Is the Investment Thesis for MBCI?
MabCure, Inc. is positioned to capitalize on the growing demand for innovative cancer detection and therapeutic solutions, driven by an increasing global cancer incidence. The company’s proprietary monoclonal antibody technology offers a unique value proposition in the oncology market, which is expected to grow substantially in the coming years. Key value drivers include the proprietary nature of its technology, which could lead to significant competitive advantages in terms of efficacy and specificity. With a gross margin of 100%, MabCure has the potential to achieve strong profitability once it successfully commercializes its products. Additionally, the ongoing advancements in cancer therapeutics and diagnostics present a favorable environment for MabCure’s offerings. However, the company must navigate challenges such as its current development stage and the need for substantial funding to advance its research initiatives. The successful execution of its business strategy could lead to significant growth and value creation for stakeholders.
Based on FMP financials and quantitative analysis
MBCI Key Highlights
Market Cap: $0.00B, indicating a need for further development and commercialization efforts.
- Profit Margin: -2490.3%, reflecting the company's current development stage and investment in R&D.
- Gross Margin: 100.0%, showcasing the potential for high profitability upon successful product commercialization.
- Beta: 9.41, indicating high volatility and risk associated with the stock.
- Dividend Yield: None, as the company is focused on growth and development rather than returning capital to shareholders.
Who Are MBCI's Competitors?
MBCI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | — |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | — |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MBCI's Key Strengths?
Proprietary technology that differentiates MabCure from competitors.
- High gross margin potential upon commercialization.
- Focused team with expertise in oncology.
What Are MBCI's Weaknesses?
Currently in development stage with no commercialized products.
- Limited financial resources and market presence.
- High beta indicating volatility and investment risk.
What Are the Key Risks for MBCI?
Financial-distress signal — its Altman Z-Score of -12.90 sits in the distress zone (elevated bankruptcy risk).
- Insider selling — insiders were net sellers of roughly $127.5B recently.
- Regulatory hurdles in obtaining approvals for new medical technologies.
- Competition from larger, established companies in the oncology sector.
- Dependence on external funding for research and development activities.
What Threats Does MBCI Face?
- Intense competition from established pharmaceutical and biotech firms.
- Regulatory challenges in bringing new medical technologies to market.
- Economic downturns affecting funding and investment in biotech.
What Are MBCI's Competitive Advantages?
- Proprietary technology for generating monoclonal antibodies.
- Focus on early cancer detection, addressing a critical need in the market.
- Strong emphasis on research and development to innovate continuously.
What Does MBCI Do?
Founded in 2006 and based in White Plains, New York, MabCure, Inc. is a development stage company that specializes in the development and commercialization of proprietary antibody technology for the early detection of cancer. Initially known as Smartec Holdings, Inc., the company underwent a name change in January 2008 to better reflect its strategic pivot towards oncology. MabCure's core innovation lies in its proprietary technology for generating monoclonal antibodies against specific cancer markers, which are critical for both early diagnosis and targeted therapeutic interventions. The company operates with a lean team of three employees, focusing on advancing its research and development efforts to bring its unique products to market. As the global cancer burden continues to rise, MabCure aims to address significant unmet medical needs through its innovative solutions. The company’s vision is to enhance cancer detection methods, ultimately leading to improved patient outcomes and survival rates. With a strong emphasis on proprietary technology, MabCure is positioned to carve out a niche in the competitive oncology landscape, leveraging its advancements to potentially transform cancer care.
What Products and Services Does MBCI Offer?
- Develop proprietary antibody technology for early cancer detection.
- Create specific therapeutics targeting cancer markers.
- Focus on monoclonal antibody generation against desired antigens.
- Engage in research and development to advance cancer diagnostics.
- Aim to commercialize innovative solutions in oncology.
- Address unmet medical needs in cancer care.
How Does MBCI Make Money?
- Generate revenue through the commercialization of proprietary cancer detection technologies.
- Engage in strategic partnerships for research and development funding.
- Potentially license technology to pharmaceutical companies for therapeutic applications.
What Industry Does MBCI Operate In?
The oncology market is experiencing significant growth, driven by rising cancer incidence rates and advancements in diagnostic and therapeutic technologies. The global cancer diagnostics market is projected to reach approximately $22 billion by 2026, reflecting a compound annual growth rate (CAGR) of around 8%. MabCure, Inc. operates within this dynamic landscape, where innovative solutions for early detection and targeted therapies are increasingly in demand. The competitive landscape includes established pharmaceutical companies and biotech firms that are also focusing on monoclonal antibodies and personalized medicine, making it essential for MabCure to differentiate itself through its proprietary technology and strategic partnerships.
Who Are MBCI's Key Customers?
- Healthcare providers seeking advanced cancer diagnostics.
- Pharmaceutical companies interested in licensing antibody technology.
- Research institutions focused on oncology research.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
5 transactions · 2 purchases, 1 sales, 2 other transactions · 2 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Financial Health
MabCure Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -12.90 places it in the distress zone, a signal of elevated financial risk.
Company Profile
MabCure Inc. operates in the Healthcare sector. It is headquartered in White Plains, US. MBCI has traded publicly since 2007.
MBCI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
MBCI Latest News
No recent news available for MBCI.
MBCI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MBCI.
Price Targets
Wall Street price target analysis for MBCI.
MBCI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MBCI; grades run from A+ (80-100) to F (below 30).
Leadership: Jehu Thomas Degerold Hand
CEO
Jehu Thomas Degerold Hand has been leading MabCure, Inc. since its inception in 2006. With a background in biotechnology and management, he has played a pivotal role in shaping the company's strategic direction and focus on oncology. His leadership is characterized by a commitment to innovation and addressing critical healthcare challenges.
Track Record: Under Jehu's leadership, MabCure has developed its proprietary antibody technology and transitioned from its previous identity as Smartec Holdings, Inc. His strategic decisions have positioned the company to explore opportunities in the oncology market.
MBCI OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers such as OTCQX or OTCQB. These companies may have limited financial disclosures and are typically smaller or in earlier stages of development, making them riskier investments compared to those listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosures may hinder investor confidence.
- Higher volatility associated with OTC stocks compared to major exchanges.
- Potential for lower trading volumes, impacting liquidity.
- Verify the company's financial health and funding status.
- Assess the progress of product development and clinical trials.
- Review management's track record and industry experience.
- Investigate any partnerships or collaborations in place.
- Examine the competitive landscape and market positioning.
- Established history since 2006 with a focus on oncology.
- Proprietary technology that could provide a competitive edge.
- Leadership with experience in biotechnology and healthcare.
What Investors Ask About MabCure Inc. (MBCI) — Healthcare
What are the main risks for MBCI?
MabCure, Inc. faces several risks, including regulatory hurdles that could delay the approval of its innovative technologies, competition from larger companies with more resources, and reliance on external funding which may be uncertain.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial disclosures may affect investor confidence.